Phaseline

Targets › ABCB1

ABCB1 (ATP-dependent translocase ABCB1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2026.

Translocates phospholipids and drugs across the membrane. Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. (UniProt, P08183)

Open in Phaseline: the race on ABCB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Texas Tech University Health Sciences CenterCurcumin
Polyphenolic compound targeting amyloid-beta aggregation and tau pathology; crosses blood-
ABCB1, APP, MAPTPhase 1BioavailabilityDec 2026

Conditions

Bioavailability (1)

Modalities

small molecule (1)

Companies

Texas Tech University Health Sciences Center (1)

Related targets

APP (1) MAPT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.